 |
|
|
| |
Two-Drug Regimen of Dolutegravir Plus Lamivudine (DTG + 3TC) Is Non-Inferior to Dolutegravir Plus Tenofovir/Emtricitabine (DTG + TDF/FTC) at 48 Weeks in Antiretroviral Treatment-Naive Adults With HIV-1 Infection: Subgroup Analyses in the GEMINI Studies
|
| |
| |
Reported by Jules Levin
Glasgow 2018 Oct 27-31
Chloe Orkin,1Norma Porteiro,2Mezgebe Berhe,3Robin Dretler,4Pompeyo Viciana,5Yu-Ting Tseng,6Cristiana Oprea,7Margaret Johnson,8Valeriy Kulagin,9Choy Man,10Jörg Sievers,11Alexander Currie,12Mark Underwood,10Allan Tenorio,10Keith Pappa,10Brian Wynne,10Michael Aboud,11Kimberly Smith,10Martin Gartland10
1Queen Mary University, London, UK; 2Fundacion IDEAA, Buenos Aires, Argentina; 3Texas Infectious Diseases Consultants, Dallas, TX, USA; 4Infectious Disease Specialists of Atlanta, Decatur, GA, USA; 5Hospital Universitario Virgen del Rocio, Sevilla, Spain; 6Kaohsiung Veterans General Hospital, Kaohsiung City, Taiwan; 7Dr. Victor Babes Clinical Hospital for Infectious and Tropical Diseases, Bucharest, Romania; 8Royal Free Hospital, London, UK; 9Clinical Center for Prevention and Treatment of AIDS and Infectious Diseases, Kasnodar, Russia; 10ViiV Healthcare, Research Triangle Park, NC, USA; 11ViiV Healthcare, Brentford, UK; 12GlaxoSmithKline, Stockley Park, UK
IAC: Non-Inferior Efficacy of Dolutegravir (DTG) Plus Lamivudine (3TC) vs DTG Plus Tenofovir/Emtricitabine (TDF/FTC) Fixed-Dose Combination in Antiretroviral Treatment-Naive Adults With HIV-1 Infection-Week 48 Results From the GEMINI Studies - (07/25/18)
|
| |
|
|
|
|
|
